In vitro study demonstrates improved SGN outcomes with customizable BDNF-releasing coatings for cochlear implants, indicating clinical potential.
Cochlear implantation (CI) remains the primary intervention for individuals with severe-to-profound sensorineural hearing loss, and its clinical outcomes can be influenced by the preservation and functional integrity of spiral ganglion neurons (SGNs). While brain-derived neurotrophic factor (BDNF) shows promising neuroprotective effects on SGNs, its clinical translation remains limited by current drug delivery methods. We present a clinically adaptable electrospinning technique using polycaprolactone/poly(ethylene oxide) (PCL/PEO) nanofibers to fabricate customizable BDNF-eluting coatings for CI electrode arrays. To enable flexible dosage adjustment tailored to surgical requirements, three modular loading protocols were developed: spray (S), spray-immersion (SI), and spray-immersion-spray (SIS). Among them, the SIS protocol demonstrated superior performance, achieving: (1) sustained BDNF release over 5 days, (2) maintenance of electrode impedance within functional ranges (2.20 ± 0.67 kΩ, n = 23), and (3) significantly enhanced SGN proliferation (p < 0.001 at 5 μg/mL) and adhesion in vitro. Importantly, our rapid electrospinning technique supports flexible customization of drug type and concentration, enabling patient-specific therapeutic loading. This method allows ultrafast coating of CI electrodes (<3 min), offering controlled drug release and consistent safety, with promising clinical translation prospects.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: